Efficacy and safety of 8 weeks versus 12 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin in patients with hepatitis C virus genotype 1 mono-infection and HIV/hepatitis C virus co-infection (C-WORTHY): a randomised, open-label phase 2 trial
Sulkowski, Mark, Dr Prof, Hezode, Christophe, Prof, Gerstoft, Jan, Prof, Vierling, John M, Prof, Mallolas, Josep, MD PhD, Pol, Stanislas, Prof, Kugelmas, Marcelo, MD, Murillo, Abel, MD, Weis, Nina, PhD, Nahass, Ronald, Prof, Shibolet, Oren, MD, Serfaty, Lawrence, MD, Bourliere, Marc, MD, DeJesus, Edwin, MD, Zuckerman, Eli, Prof, Dutko, Frank, PhD, Shaughnessy, Melissa, MS, Hwang, Peggy, PhD, Howe, Anita Y M, PhD, Wahl, Janice, MD, Robertson, Michael, MD, Barr, Eliav, MD, Haber, Barbara, MD
Published in The Lancet (British edition) (21.03.2015)
Published in The Lancet (British edition) (21.03.2015)
Get full text
Journal Article
Switch to a raltegravir-based regimen versus continuation of a lopinavir-ritonavir-based regimen in stable HIV-infected patients with suppressed viraemia (SWITCHMRK 1 and 2): two multicentre, double-blind, randomised controlled trials
Eron, Joseph J, Prof, Young, Benjamin, MD, Cooper, David A, Prof, Youle, Michael, MD, DeJesus, Edwin, MD, Andrade-Villanueva, Jaime, MD, Workman, Cassy, MD, Zajdenverg, Roberto, MD, Fätkenheuer, Gerd, Prof, Berger, Daniel S, MD, Kumar, Princy N, MD, Rodgers, Anthony J, MS, Shaughnessy, Melissa A, MS, Walker, Monica L, BS, Barnard, Richard JO, PhD, Miller, Michael D, PhD, DiNubile, Mark J, MD, Nguyen, Bach-Yen, MD, Leavitt, Randi, MD, Xu, Xia, PhD, Sklar, Peter, Dr
Published in The Lancet (British edition) (01.01.2010)
Published in The Lancet (British edition) (01.01.2010)
Get full text
Journal Article
Efficacy and safety of 12 weeks versus 18 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin for hepatitis C virus genotype 1 infection in previously untreated patients with cirrhosis and patients with previous null response with or without cirrhosis (C-WORTHY): a randomised, open-label phase 2 trial
Lawitz, Eric, Prof, Gane, Edward, Prof, Pearlman, Brian, Prof, Tam, Edward, MD, Ghesquiere, Wayne, Prof, Guyader, Dominique, Prof, Alric, Laurent, MD, Bronowicki, Jean-Pierre, Prof, Lester, Laura, MSN, Sievert, William, Prof, Ghalib, Reem, MD, Balart, Luis, MD, Sund, Fredrik, MD, Lagging, Martin, Prof, Dutko, Frank, PhD, Shaughnessy, Melissa, MS, Hwang, Peggy, PhD, Howe, Anita Y M, PhD, Wahl, Janice, MD, Robertson, Michael, MD, Barr, Eliav, MD, Haber, Barbara, MD
Published in The Lancet (British edition) (21.03.2015)
Published in The Lancet (British edition) (21.03.2015)
Get full text
Journal Article
Efficacy and safety of grazoprevir (MK-5172) and elbasvir (MK-8742) in patients with hepatitis C virus and HIV co-infection (C-EDGE CO-INFECTION): a non-randomised, open-label trial
Rockstroh, Jürgen K, Nelson, Mark, Katlama, Christine, Lalezari, Jay, Mallolas, Josep, Bloch, Mark, Matthews, Gail V, Saag, Michael S, Zamor, Philippe J, Orkin, Chloe, Gress, Jacqueline, Klopfer, Stephanie, Shaughnessy, Melissa, Wahl, Janice, Nguyen, Bach-Yen T, Barr, Eliav, Platt, Heather L, Robertson, Michael N, Sulkowski, Mark
Published in The lancet HIV (01.08.2015)
Published in The lancet HIV (01.08.2015)
Get more information
Journal Article
Efficacy and safety of a two‐drug direct‐acting antiviral agent regimen ruzasvir 180 mg and uprifosbuvir 450 mg for 12 weeks in adults with chronic hepatitis C virus genotype 1, 2, 3, 4, 5 or 6
Lawitz, Eric, Gane, Edward, Feld, Jordan J., Buti, Maria, Foster, Graham R., Rabinovitz, Mordechai, Burnevich, Eduard, Katchman, Helena, Tomasiewicz, Krzysztof, Lahser, Fred, Jackson, Beth, Shaughnessy, Melissa, Klopfer, Stephanie, Yeh, Wendy W., Robertson, Michael N., Hanna, George J., Barr, Eliav, Platt, Heather L., Gordon, Stuart C., Lawitz, Eric J., Ruane, Peter Jerome, Sahota, Amandeep, Terrault, Norah A., Tsai, Naoky, Kalathil, Sumodh C., Reddy, Gautham, Ghesquiere, Wayne, Borgia, Sergio, Conway, Brian, Feld, Jordan, Tsoi, Keith, Cooper, Curtis L., Ghali, Peter Maged, Thompson, Alexander James Venn, Panero, Jose Luis Calleja, Ferret, Sabela Lens Maria Buti, Franinan, Luis Margusino, Angeles Castro Iglesias, Maria, Brown, Ashley, Agarwal, Kaushik, Foster, Graham, Cramp, Matthew, Zuckerman, Eli, Veitsman, Ella, Cohen, Michal, Lurie, Yoav, Ari, Ziv Ben, Janczewska, Ewa, Szymczak, Aleksandra, Halota, Waldemar, Flisiak, Robert, Mahomed, Adam, Sonderup, Mark Wayne, Punt, Zelda Erika, Kgomo, Mpho Klaas, Bernhardi, David C, Burnevich, Eduard Z., Kizhlo, Svetlana
Published in Journal of viral hepatitis (01.09.2019)
Published in Journal of viral hepatitis (01.09.2019)
Get full text
Journal Article
Efficacy and safety of MK-5172 and MK-8742 +/- ribavirin in hepatitis C genotype 1 infected patients with cirrhosis or previous null response: Final results of the C-WORTHY Study (Parts A and B)
Lawitz, Eric, Gane, Edward J., Pearlman, Brian, Tam, Edward, Ghesquiere, Wayne, Guyader, Dominique, Alric, Laurent, Bronowicki, Jean-Pierre, Rossaro, Lorenzo, Sievert, William, Ghalib, Reem H., Balart, Luis A., Sund, Fredrik, Lagging, Martin, Dutko, Frank, Howe, Anita Y., Shaughnessy, Melissa, Hwang, Peggy, Wahl, Janice, Robertson, Michael, Haber, Barbara A.
Published in Hepatology (Baltimore, Md.) (2014)
Get full text
Published in Hepatology (Baltimore, Md.) (2014)
Journal Article